Can-Fite BioPharma (CANF) has secured a patent in Japan covering the use of certain adenosine receptor agonists, including its Namodenoson lead drug candidate, for inducing fat loss and treating obesity and related metabolic disorders, the company said Friday.
The company has already secured patent protection for the technology in the US, Canada, Australia and other major regions, it said.
Can-Fite shares were up 18% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments